今日港股生物科技股份公司荣昌生物(09995)股价大涨11.26%,引发了市场的广泛关注。这得益于该公司在宫颈癌治疗领域取得新的突破性进展。
消息显示,荣昌生物自主研发的抗体偶联药物维迪西妥单抗,与卡度尼利单抗联合治疗复发或转移性宫颈癌的"爱卡"方案二期临床研究结果首次在国际会议上公布,疗效令人鼓舞。该方案由中山大学肿瘤防治中心主导,是全球首个HER2靶向ADC和免疫疗法联合治疗宫颈癌的临床试验。
业内人士表示,荣昌生物这一联合疗法创新性极强,维迪西妥单抗能够精准递送细胞毒素至肿瘤细胞内部,而卡度尼利单抗则增强机体抗肿瘤免疫,两者有望通力协作打破宫颈癌治疗瓶颈。此外,公司还在多个其他癌种中开展了ADC药物的临床研究,预计会取得更多突破性成果。市场对荣昌生物未来的长期增长潜力充满期待,当前大涨也呼应了多数机构对其保持"买入"评级。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.